Results 21 to 30 of about 710 (119)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

open access: yesРациональная фармакотерапия в кардиологии, 2015
Aim. Carriership of CYP2C19*2 allelic variant and reduced CYP3A4 activity can affect the formation of clopidogrel’s active metabolite and, respectively, its antiplatelet effect.
K. B. Mirzaev   +4 more
doaj   +1 more source

Morphological determinants for the local hemostatic effect of exogenous fibrin monomer in its systemic administration after injury with inhibition of platelet aggregation in the experiment

open access: yesActa Biomedica Scientifica, 2023
Background. In our previously published studies, we demonstrated a high hemostatic activity of a low dose of exogenous fibrin monomer during its systemic administration in a model of dosed liver injury with preliminary inhibition of platelet aggregation.
V. M. Vdovin   +6 more
doaj   +1 more source

Spontaneous coronary artery dissection (scad) [PDF]

open access: yes, 2014
Spontaneous coronary artery dissection is rare disease, occurring most often in young women. Clinical manifestation is acute coronary syndrome (ACS). Patogenetic of the disease is not known.
Groch, Ladislav   +2 more
core   +2 more sources

Механическая поддержка кровообращения у детей: патофизиология педиатрического гемостаза и алгоритмы послеоперационного ведения [PDF]

open access: yes, 2023
Chronic heart failure (CHF) against the background of congenital heart disease, mostly in early childhood, or various forms of cardiomyopathies, more common in teenage age, represents an important cause of morbidity and mortality in the pediatric ...
D. V. Ryabtsev   +7 more
core   +2 more sources

EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE

open access: yesРациональная фармакотерапия в кардиологии, 2015
Evaluation of platelet function with subsequent modification of antiplatelet therapy regimen is one of the areas of personalized medicine. Analysis of the causes of inadequate antiplatelet action of clopidogrel, the association of residual platelet ...
K. B. Mirzaev   +2 more
doaj   +1 more source

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS

open access: yesРациональная фармакотерапия в кардиологии, 2016
Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy in patients with cardioascular diseases are discussed.
O. V. Gaisenok
doaj   +1 more source

ИЗМЕНИЛИСЬ ЛИ НАШИ ПРЕДСТАВЛЕНИЯ О НЕОБХОДИМОСТИ КЛОПИДОГРЕЛА В ЛЕЧЕНИИ КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ С ПОЯВЛЕНИЕМ БОЛЕЕ МОЩНЫХ АНТИАГРЕГАНТОВ? [PDF]

open access: yes, 2017
Despite the decline in cardiovascular mortality rate in recent decades due to the widespread use of antihypertensive, hypocholesterolemic and antiplatelet drugs, various manifestations of ischemic heart disease (IHD) retain one-third of the mortality ...
E. P. PANCHENKO   +1 more
core   +2 more sources

THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original clopidogrel (Plavix) and its generic (Egitromb) in patients of high cardiovascular risk. Material and methods.
V. V. Yakusevich   +4 more
doaj   +1 more source

Исследование остеопротективных эффектов тетрагидробиоптерина и клопедогрела на модели гипоэстрогенного остеопороза [PDF]

open access: yes, 2014
Изучение и анализ остеопротективных свойств тетрагидробиоптерина и клопидогрела при экспериментальном остеопорозе у ...
Гудырев, О. С.   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy